Analysts See $-0.17 EPS for Titan Pharmaceuticals, Inc. (TTNP)

February 24, 2018 - By Marguerite Chambers

 Analysts See $ 0.17 EPS for Titan Pharmaceuticals, Inc. (TTNP)

Analysts expect Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) to report $-0.17 EPS on March, 15.They anticipate $0.02 EPS change or 13.33 % from last quarter’s $-0.15 EPS. After having $-0.20 EPS previously, Titan Pharmaceuticals, Inc.’s analysts see -15.00 % EPS growth. It closed at $1 lastly. It is down 59.84% since February 24, 2017 and is downtrending. It has underperformed by 76.54% the S&P500.

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops proprietary therapeutics for the treatment of serious medical disorders in the United States. The company has market cap of $21.20 million. It develops products based on ProNeura, a proprietary long-term drug delivery technology that focuses primarily on treatments for chronic diseases. It currently has negative earnings. The firm offers Probuphine, a product candidate for long term maintenance treatment of opioid dependence, which maintains a stable, around the clock blood level of the drug buprenorphine in patients for six months following a single treatment.

More notable recent Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) news were published by: which released: “Titan Pharmaceuticals: Outlook For Probuphine” on May 23, 2017, also with their article: “Titan Pharmaceuticals Is About To Pop” published on January 31, 2017, published: “Titan Pharmaceuticals: Bravery Will Be Rewarded (Just Maybe Not This Year)” on March 24, 2017. More interesting news about Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) were released by: and their article: “Titan Pharmaceuticals: Just Be Patient” published on July 20, 2017 as well as‘s news article titled: “Titan Pharmaceuticals and Walter Reed Army Institute of Research Collaborate …” with publication date: July 06, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: